For the quarter ended December 2025, Merit Medical (MMSI) reported revenue of $393.94 million, up 10.9% over the same period last year. EPS came in at $1.04, compared to $0.93 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $390.83 million, representing a surprise of +0.8%. The company delivered an EPS surprise of +8.9%, with the consensus EPS estimate being $0.96.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Merit Medical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Sales- United States: $238.22 million compared to the $234.37 million average estimate based on two analysts. The reported number represents a change of +11.6% year over year.
- Geographic Sales- APAC: $62.72 million versus $60.69 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +3.1% change.
- Geographic Sales- International: $155.71 million compared to the $152.71 million average estimate based on two analysts. The reported number represents a change of +10% year over year.
- Geographic Sales- Rest of World: $15.62 million versus the two-analyst average estimate of $15.31 million. The reported number represents a year-over-year change of -0.2%.
- Geographic Sales- EMEA: $77.37 million compared to the $76.71 million average estimate based on two analysts. The reported number represents a change of +18.8% year over year.
- Revenue- Cardiovascular- Peripheral Intervention: $154.93 million compared to the $148.66 million average estimate based on five analysts. The reported number represents a change of +10.4% year over year.
- Revenue- Cardiovascular- Cardiac Intervention: $117.24 million versus $111.56 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +22.5% change.
- Revenue- Endoscopy: $20.06 million compared to the $19.97 million average estimate based on five analysts. The reported number represents a change of +14.9% year over year.
- Revenue- Cardiovascular- OEM: $48.09 million compared to the $55.76 million average estimate based on five analysts. The reported number represents a change of -4.7% year over year.
- Revenue- Cardiovascular: $373.88 million compared to the $368.79 million average estimate based on five analysts. The reported number represents a change of +10.7% year over year.
- Revenue- Cardiovascular- Custom Procedural Solutions: $53.62 million versus $52.82 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +4.7% change.
View all Key Company Metrics for Merit Medical here>>>
Shares of Merit Medical have returned -1.1% over the past month versus the Zacks S&P 500 composite's -1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Merit Medical Systems, Inc. (MMSI): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
